HRP20211145T1 - Novi genetski modificiran virus vakcinije - Google Patents
Novi genetski modificiran virus vakcinije Download PDFInfo
- Publication number
- HRP20211145T1 HRP20211145T1 HRP20211145TT HRP20211145T HRP20211145T1 HR P20211145 T1 HRP20211145 T1 HR P20211145T1 HR P20211145T T HRP20211145T T HR P20211145TT HR P20211145 T HRP20211145 T HR P20211145T HR P20211145 T1 HRP20211145 T1 HR P20211145T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- vaccinia virus
- polynucleotide encoding
- pharmaceutical preparation
- cell lung
- Prior art date
Links
- 241000700618 Vaccinia virus Species 0.000 title claims 35
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 102000013462 Interleukin-12 Human genes 0.000 claims 7
- 108010065805 Interleukin-12 Proteins 0.000 claims 7
- 102000000704 Interleukin-7 Human genes 0.000 claims 7
- 108010002586 Interleukin-7 Proteins 0.000 claims 7
- 229940117681 interleukin-12 Drugs 0.000 claims 7
- 229940100994 interleukin-7 Drugs 0.000 claims 7
- 230000002950 deficient Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010027406 Mesothelioma Diseases 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 101800003344 Vaccinia growth factor Proteins 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (21)
1. Virus vakcinije koji sadrži sljedeće (1) i (2):
(1) polinukleotid koji kodira interleukin-7 (IL-7); i
(2) polinukleotid koji kodira interleukin-12 (IL-12).
2. Farmaceutski pripravak koji sadrži sljedeće viruse vakcinije (1) i (2):
(1) virus vakcinije koji sadrži polinukleotid koji kodira IL-7; i
(2) virus vakcinije koji sadrži polinukleotid koji kodira IL-12.
3. Kombinirani komplet koji sadrži sljedeće viruse vakcinije (1) i (2):
(1) virus vakcinije koji sadrži polinukleotid koji kodira IL-7; i
(2) virus vakcinije koji sadrži polinukleotid koji kodira IL-12.
4. Virus vakcinije prema patentnom zahtjevu 1, naznačen time što virus vakcinije ima nedostatak u funkciji faktora rasta virusa vakcinije (VGF) i/ili
pri čemu virus vakcinije ima nedostatak u funkciji O1L.
5. Virus vakcinije prema patentnom zahtjevu 1, naznačen time što virus vakcinije ima deleciju u domenama kratkog konsenzusnog ponavljanja (SCR) u izvanstaničnoj regiji B5R.
6. Virus vakcinije prema patentnom zahtjevu 1, naznačen time što virus vakcinije ima nedostatak u funkcijama VGF i O1L i ima deleciju u SCR domenama u izvanstaničnoj regiji B5R.
7. Virus vakcinije prema bilo kojem od patentnih zahtjeva 1 i 4-6, naznačen time što je virus vakcinije soj LC16mO.
8. Farmaceutski pripravak naznačen time što sadrži virus vakcinije prema bilo kojem od patentnih zahtjeva 1 i 4-7 i farmaceutski prihvatljivu pomoćnu tvar.
9. Farmaceutski pripravak prema patentnom zahtjevu 2 ili komplet prema patentnom zahtjevu 3, naznačen time što virus vakcinije ima nedostatak u funkciji VGF i/ili pri čemu virus vakcinije ima nedostatak u funkciji O1L.
10. Farmaceutski pripravak prema patentnom zahtjevu 2 ili komplet prema patentnom zahtjevu 3, naznačen time što virus vakcinije ima deleciju u SCR domenama u izvanstaničnoj regiji B5R.
11. Farmaceutski pripravak prema patentnom zahtjevu 2 ili komplet prema patentnom zahtjevu 3, naznačen time što virus vakcinije ima nedostatak u funkcijama VGF i O1L i ima deleciju u SCR domenama u izvanstaničnoj regiji B5R.
12. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 2 i 9-11 ili komplet prema bilo kojem od patentnih zahtjeva 3 i 9-11, naznačen time što je virus vakcinije soj LC16mO.
13. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 2 i 9-12 ili komplet prema bilo kojem od patentnih zahtjeva 3 i 9-12, naznačen time što nadalje sadrži farmaceutski prihvatljivu pomoćnu tvar.
14. Farmaceutski pripravak ili komplet prema bilo kojem od patentnih zahtjeva 8-13, naznačen time što je za uporabu u postupku za prevenciju ili liječenje raka.
15. Farmaceutski pripravak ili komplet za uporabu prema patentnom zahtjevu 14, naznačen time što je rak maligni melanom, adenokarcinom pluća, rak pluća, karcinom pluća malih stanica, karcinom skvamoznih stanica pluća, rak bubrega, rak mokraćnog mjehura, rak glave i vrata, rak dojke, rak jednjaka, glioblastom, neuroblastom, mijelom, rak jajnika, kolorektalni karcinom, rak gušterače, rak prostate, hepatocelularni karcinom, mezoteliom, rak vrata maternice ili rak želuca.
16. Virus vakcinije prema bilo kojem od patentnih zahtjeva 1 i 4-7, naznačen time što je za uporabu u postupku za prevenciju ili liječenje raka.
17. Virus vakcinije za uporabu prema patentnom zahtjevu 16, naznačen time što je rak maligni melanom, adenokarcinom pluća, rak pluća, karcinom pluća malih stanica, karcinom skvamoznih stanica pluća, rak bubrega, rak mokraćnog mjehura, rak glave i vrata, rak dojke, rak jednjaka, glioblastom, neuroblastom, mijelom, rak jajnika, kolorektalni karcinom, rak gušterače, rak prostate, hepatocelularni karcinom, mezoteliom, rak vrata maternice ili rak želuca.
18. Virus vakcinije koji sadrži polinukleotid koji kodira IL-7 i virus vakcinije koji sadrži polinukleotid koji kodira IL-12 za uporabu u postupku za prevenciju ili liječenje raka, te postupak obuhvaća korak davanja virusa vakcinije subjektu kojem je potrebna prevencija ili liječenje raka.
19. Virus vakcinije za uporabu prema patentnom zahtjevu 18, naznačen time što je rak maligni melanom, adenokarcinom pluća, rak pluća, karcinom pluća malih stanica, karcinom skvamoznih stanica pluća, rak bubrega, rak mokraćnog mjehura, rak glave i vrata, rak dojke, rak jednjaka, glioblastom, neuroblastom, mijelom, rak jajnika, kolorektalni karcinom, rak gušterače, rak prostate, hepatocelularni karcinom, mezoteliom, rak vrata maternice ili rak želuca.
20. Virus vakcinije odabran između sljedećih (1) ili (2):
(1) virusa vakcinije koji sadrži polinukleotid koji kodira IL-7, za uporabu u postupku prevencije ili liječenja raka u kombinaciji s farmaceutskim pripravkom koji sadrži virus vakcinije koji sadrži polinukleotid koji kodira IL-12; ili
(2) virusa vakcinije koji sadrži polinukleotid koji kodira IL-12, za uporabu u postupku prevencije ili liječenja raka u kombinaciji s farmaceutskim pripravkom koji sadrži virus vakcinije koji sadrži polinukleotid koji kodira IL-7.
21. Virus vakcinije za uporabu prema patentnom zahtjevu 20, naznačen time što je rak maligni melanom, adenokarcinom pluća, rak pluća, karcinom pluća malih stanica, karcinom skvamoznih stanica pluća, rak bubrega, rak mokraćnog mjehura, rak glave i vrata, rak dojke, rak jednjaka, glioblastom, neuroblastom, mijelom, rak jajnika, kolorektalni karcinom, rak gušterače, rak prostate, hepatocelularni karcinom, mezoteliom, rak vrata maternice ili rak želuca.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016107481 | 2016-05-30 | ||
| EP17806608.0A EP3480307B1 (en) | 2016-05-30 | 2017-05-29 | New genetically-modified vaccinia virus |
| PCT/JP2017/019921 WO2017209053A1 (ja) | 2016-05-30 | 2017-05-29 | 新規な遺伝子組換えワクシニアウイルス |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211145T1 true HRP20211145T1 (hr) | 2021-12-24 |
Family
ID=60477559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211145TT HRP20211145T1 (hr) | 2016-05-30 | 2017-05-29 | Novi genetski modificiran virus vakcinije |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP3480307B1 (hr) |
| JP (1) | JP6794442B2 (hr) |
| KR (1) | KR102357051B1 (hr) |
| CN (1) | CN109477089B (hr) |
| AR (1) | AR108630A1 (hr) |
| AU (1) | AU2017272721B2 (hr) |
| BR (1) | BR112018074881A2 (hr) |
| CA (1) | CA3026025A1 (hr) |
| CO (1) | CO2018013738A2 (hr) |
| CY (1) | CY1124314T1 (hr) |
| DK (1) | DK3480307T3 (hr) |
| ES (1) | ES2882538T3 (hr) |
| HR (1) | HRP20211145T1 (hr) |
| HU (1) | HUE054967T2 (hr) |
| IL (1) | IL263373B2 (hr) |
| LT (1) | LT3480307T (hr) |
| MX (1) | MX2018014779A (hr) |
| MY (1) | MY191091A (hr) |
| PH (1) | PH12018502548A1 (hr) |
| PL (1) | PL3480307T3 (hr) |
| PT (1) | PT3480307T (hr) |
| RS (1) | RS62077B1 (hr) |
| RU (1) | RU2757933C2 (hr) |
| SG (1) | SG11201810612TA (hr) |
| SI (1) | SI3480307T1 (hr) |
| TW (1) | TWI763673B (hr) |
| UA (1) | UA126380C2 (hr) |
| WO (1) | WO2017209053A1 (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108686202A (zh) * | 2017-04-06 | 2018-10-23 | 张晋宇 | 肿瘤免疫疗法 |
| JP7274138B2 (ja) * | 2017-11-30 | 2023-05-16 | アステラス製薬株式会社 | Ｓｃｒ欠失ワクシニアウイルス |
| MX2020007010A (es) | 2018-01-05 | 2020-12-10 | Ottawa Hospital Res Inst | Vectores modificados de orthopoxvirus. |
| CA3113965A1 (en) | 2018-09-26 | 2020-04-02 | Astellas Pharma Inc. | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
| CN110205307A (zh) * | 2019-01-07 | 2019-09-06 | 西安彤盛生物科技有限公司 | 去除vgf基因的重组天坛株溶瘤痘苗病毒及制备和应用 |
| US20220313761A1 (en) * | 2019-05-14 | 2022-10-06 | National University Corporation Tottori University | Vaccinia virus that induces cell fusion and use thereof |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| AU2020337690A1 (en) * | 2019-08-29 | 2022-04-07 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| CN115103681B (zh) * | 2020-02-18 | 2023-10-31 | 苏州工业园区唯可达生物科技有限公司 | 一种重组病毒载体、包含其的免疫组合物以及用途 |
| JP2023532768A (ja) | 2020-07-07 | 2023-07-31 | バイオエヌテック エスエー | Ｈｐｖ陽性癌の治療用ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| EP4370552A1 (en) | 2021-07-13 | 2024-05-22 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
| CA3233512A1 (en) | 2021-10-06 | 2023-04-13 | Alexander Muik | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| IL149184A0 (en) | 1999-10-18 | 2002-11-10 | St Vincent S Hospital And Medi | Melanoma vaccine and methods of making and using same |
| CN100562570C (zh) | 2003-06-18 | 2009-11-25 | 吉恩勒克斯公司 | 修饰的重组痘苗病毒及其它微生物,及其应用 |
| US20070036758A1 (en) | 2003-07-08 | 2007-02-15 | Bertram Jacobs | Mutants of vaccinia virus as oncolytic agents |
| EP1518932A1 (en) | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
| EP2150618B1 (en) * | 2007-05-04 | 2017-10-11 | University Health Network | Il-12 immunotherapy for cancer |
| RU2612788C2 (ru) * | 2010-03-23 | 2017-03-13 | Интрексон Корпорейшн | Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение |
| JP5652830B2 (ja) * | 2010-04-09 | 2015-01-14 | 国立大学法人 東京大学 | マイクロｒｎａ制御組換えワクシニアウイルス及びその使用 |
| WO2012151272A2 (en) * | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| CA2758246C (en) | 2011-11-16 | 2013-02-12 | Westport Power Inc. | Method and apparatus for pumping fuel to a fuel injection system |
| EP3072966B1 (en) * | 2013-11-21 | 2020-01-08 | National University Corporation Tottori University | Mitogen-activated protein kinase-dependent recombinant vaccinia virus (md-rvv) and use thereof |
| GB201405834D0 (en) * | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
-
2017
- 2017-05-29 LT LTEPPCT/JP2017/019921T patent/LT3480307T/lt unknown
- 2017-05-29 MY MYPI2018002210A patent/MY191091A/en unknown
- 2017-05-29 WO PCT/JP2017/019921 patent/WO2017209053A1/ja unknown
- 2017-05-29 PT PT178066080T patent/PT3480307T/pt unknown
- 2017-05-29 EP EP17806608.0A patent/EP3480307B1/en active Active
- 2017-05-29 SI SI201730831T patent/SI3480307T1/sl unknown
- 2017-05-29 CN CN201780033837.8A patent/CN109477089B/zh active Active
- 2017-05-29 PL PL17806608T patent/PL3480307T3/pl unknown
- 2017-05-29 RU RU2018146490A patent/RU2757933C2/ru active
- 2017-05-29 RS RS20210847A patent/RS62077B1/sr unknown
- 2017-05-29 HR HRP20211145TT patent/HRP20211145T1/hr unknown
- 2017-05-29 DK DK17806608.0T patent/DK3480307T3/da active
- 2017-05-29 HU HUE17806608A patent/HUE054967T2/hu unknown
- 2017-05-29 MX MX2018014779A patent/MX2018014779A/es unknown
- 2017-05-29 UA UAA201812814A patent/UA126380C2/uk unknown
- 2017-05-29 ES ES17806608T patent/ES2882538T3/es active Active
- 2017-05-29 IL IL263373A patent/IL263373B2/en unknown
- 2017-05-29 CA CA3026025A patent/CA3026025A1/en active Pending
- 2017-05-29 BR BR112018074881-1A patent/BR112018074881A2/pt unknown
- 2017-05-29 AU AU2017272721A patent/AU2017272721B2/en active Active
- 2017-05-29 KR KR1020187037642A patent/KR102357051B1/ko active IP Right Grant
- 2017-05-29 JP JP2018520896A patent/JP6794442B2/ja active Active
- 2017-05-29 AR ARP170101463A patent/AR108630A1/es unknown
- 2017-05-29 SG SG11201810612TA patent/SG11201810612TA/en unknown
- 2017-05-31 TW TW106117938A patent/TWI763673B/zh active
-
2018
- 2018-12-03 PH PH12018502548A patent/PH12018502548A1/en unknown
- 2018-12-18 CO CONC2018/0013738A patent/CO2018013738A2/es unknown
-
2021
- 2021-07-16 CY CY20211100643T patent/CY1124314T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211145T1 (hr) | Novi genetski modificiran virus vakcinije | |
| MX2019010459A (es) | Vacuna. | |
| MX2022014644A (es) | Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapeuticos contra tumores solidos. | |
| MX2016010266A (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| JP2018507249A5 (hr) | ||
| MX2017010336A (es) | Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn. | |
| MX2019013276A (es) | Virus de la enfermedad de newcastle y usos de los mismos. | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| MX2018002524A (es) | Composicion farmaceutica que contiene, como ingrediente activo, proteina de fusion en la que el peptido de tumor-penetrante y el agente anti-angiogenesis se funden, para prevenir y tratar el cancer o enfermedades relacionadas a la angiogenesis. | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| MX2020006530A (es) | Virus recombinante con region desoptimizada de par de codones y usos del mismo para el tratamiento de cancer. | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| WO2014153166A3 (en) | Therapeutic use of antibodies to hgf | |
| MX2017000886A (es) | Tratamiento con cis-clomifeno de sofocos y perdida osea inducidos por privacion de androgeno terapeutica. | |
| PH12017500088A1 (en) | Antagonists of neurokinin b in fish reproduction | |
| EP3510014A4 (en) | COMPOSITIONS AND METHODS FOR USE OF GAMMA KETOALDEHYD CATCHERS FOR TREATING, PREVENTING OR IMPROVING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD, OR DISEASES | |
| WO2016111523A3 (ko) | HNF4-α 길항제 및 이의 용도 | |
| MY194889A (en) | Divalent vaccine compositions and the use thereof for treating tumors | |
| Jiang et al. | Asymmetric Oxidative Carbocyclization-Borylation of Enallenes | |
| Tian et al. | Asymmetric Chromium-Catalyzed Dearomative 1, 2-Addition | |
| MX2019004345A (es) | Formas cristalinas de 4-(2-((1r,2r)-2-hidroxiciclohexilamino) benzotiazol-6-iloxi)-n-metilpicolinamida. | |
| MX2018003081A (es) | Una composicion para uso en el tratamiento del dolor relacionado con los discos intervertebrales. | |
| HRP20200080T1 (hr) | Terapija raka parvovirusom h-1 u kombinaciji s anti-pd1 antitijelom ili anti pd-l-1 antitijelom | |
| MX2021013822A (es) | Virus de fiebre amarilla atenuado y usos del mismo para el tratamiento de cancer. |